Acerus Drug Patent Portfolio
Acerus owns 2 orange book drugs protected by 12 US patents Given below is the list of Acerus's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11090312 | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event | 17 Mar, 2034 | Active |
| US11744838 | Methods Of Treating Hypogonadism With Transnasal Testosterone Bio-Adhesive Gel Formulations In Male With Allergic Rhinitis, And Methods For Preventing An Allergic Rhinitis Event | 17 Mar, 2034 | Active |
| US11419914 | Safe desmopressin administration | 15 Jun, 2030 | Active |
| US12090190 | Safe desmopressin administration | 15 Jun, 2030 | Active |
| US9539302 | Safe desmopressin administration | 15 Jun, 2030 | Active |
| US7799761 | Pharmaceutical compositions including low dosages of desmopressin | 26 Sep, 2024 | Expired |
| US8574622 | Controlled release delivery system for nasal applications | 04 Feb, 2024 | Expired |
| US8784869 | Controlled release delivery system for nasal applications and methods of treatment | 04 Feb, 2024 | Expired |
| US8784882 | Controlled release delivery system for nasal applications and method of treatment | 04 Feb, 2024 | Expired |
| US8877230 | Controlled release delivery system for nasal applications | 04 Feb, 2024 | Expired |
| US7405203 | Pharmaceutical compositions including low dosages of desmopressin | 06 May, 2023 | Expired |
| US7579321 | Pharmaceutical compositions including low dosages of desmopressin | 06 May, 2023 | Expired |
Latest Legal Activities on Acerus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Acerus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed | 23 Jun, 2025 | US8574622 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 11 Jan, 2025 | US11090312 |
| Email Notification | 26 Nov, 2024 | US12090190 |
| Patent eCofC Notification | 26 Nov, 2024 | US12090190 |
| Mail Patent eCofC Notification | 26 Nov, 2024 | US12090190 |
| Recordation of Patent eCertificate of Correction | 26 Nov, 2024 | US12090190 |
| Post Issue Communication - Certificate of Correction | 07 Nov, 2024 | US12090190 |
| Patent Issue Date Used in PTA Calculation | 17 Sep, 2024 | US12090190 |
| Recordation of Patent eGrant | 17 Sep, 2024 | US12090190 |
| Recordation of Patent Grant Mailed | 17 Sep, 2024 | US12090190 |
| Mail Patent eGrant Notification | 17 Sep, 2024 | US12090190 |
| Patent eGrant Notification | 17 Sep, 2024 | US12090190 |
| Email Notification | 17 Sep, 2024 | US12090190 |
| Email Notification | 29 Aug, 2024 | US12090190 |
| Issue Notification Mailed | 28 Aug, 2024 | US12090190 |
Acerus Drug Patents' Oppositions Filed in EPO
Acerus drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 12, 2018, by Ferring B.V.. This opposition was filed on patent number EP10790053A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17168865A | Aug, 2020 | Ferring B.V. | Revoked |
| EP09796558A | May, 2019 | Ferring B.V. | Patent maintained as amended |
| EP10790053A | Mar, 2018 | Ferring B.V. | Granted and Under Opposition |
Acerus's Family Patents
Acerus Drug List
Given below is the complete list of Acerus's drugs and the patents protecting them.
1. Natesto
Natesto is protected by 6 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11090312 | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
17 Mar, 2034
(8 years from now)
| Active |
| US11744838 | Methods Of Treating Hypogonadism With Transnasal Testosterone Bio-Adhesive Gel Formulations In Male With Allergic Rhinitis, And Methods For Preventing An Allergic Rhinitis Event |
17 Mar, 2034
(8 years from now)
| Active |
| US8574622 | Controlled release delivery system for nasal applications |
04 Feb, 2024
(2 years ago)
| Expired |
| US8784869 | Controlled release delivery system for nasal applications and methods of treatment |
04 Feb, 2024
(2 years ago)
| Expired |
| US8784882 | Controlled release delivery system for nasal applications and method of treatment |
04 Feb, 2024
(2 years ago)
| Expired |
| US8877230 | Controlled release delivery system for nasal applications |
04 Feb, 2024
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Natesto's drug page
2. Noctiva
Noctiva is protected by 6 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11419914 | Safe desmopressin administration |
15 Jun, 2030
(4 years from now)
| Active |
| US12090190 | Safe desmopressin administration |
15 Jun, 2030
(4 years from now)
| Active |
| US9539302 | Safe desmopressin administration |
15 Jun, 2030
(4 years from now)
| Active |
| US7799761 | Pharmaceutical compositions including low dosages of desmopressin |
26 Sep, 2024
(1 year, 5 months ago)
| Expired |
| US7405203 | Pharmaceutical compositions including low dosages of desmopressin |
06 May, 2023
(2 years ago)
| Expired |
| US7579321 | Pharmaceutical compositions including low dosages of desmopressin |
06 May, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Noctiva's drug page